Loading dashboard
Experiments tailored to you
See what actually works for you. Connect your health data and track your progress.
Breathing pure oxygen in a pressurized chamber, where the pressure dissolves extra oxygen directly into blood plasma to reach tissue that normal circulation may not supply enough.
The most defensible Murph page is a tracking wrapper for prescribed systemic chamber HBOT: it can document dose fidelity, supervision, tolerability, and adverse events while keeping efficacy claims tied to specific clinical indications.
HBOT is best represented as a high-caution, clinician-supervised medical therapy with indication-specific evidence, not as a general wellness or longevity protocol.
Evidence strength varies sharply by indication and comparator; adjacent oxygen variants and commercial wellness claims should not inherit systemic clinical HBOT evidence.
Sources checked is every card shown on this page. Direct human participants counts only primary human studies with coded participant totals, deduplicated by cohort when possible. Review cards may show larger pooled head counts on their own rows, and those pooled totals are treated as approximate rather than added into the page-level number.
Whole-body chamber HBOT with explicit oxygen/pressure dosing and facility supervision is the canonical protocol boundary. Supervision, credentialing, device controls, and fire-safety systems are part of the intervention rather than optional extras.
9 sources · 9 guidance sources
U.S. coverage anchor defining HBOT as whole-body exposure and listing covered vs non-covered indication classes.
Authoritative regulator communication on recent serious injuries and deaths plus preventive actions. Also surfaced in shard(s): boundary-guidelines, adjacent-modalities-and-external-claims. Canonicalized on exact URL.
Operational supervision statement that specifies direct supervision expectations and immediate physician availability.
Foundational older European practice code that remains useful for historical boundary-setting and practice evolution.
Comprehensive practice code covering operational, supervision, and treatment-process boundaries for HBOT.
Peer-reviewed UHMS position statement detailing physician responsibilities for HBOT prescription, monitoring, and proximity.
Major facility operations reference used by accredited HBOT programs and cited in UHMS safety materials.
Direct U.S. practice-standard document on who may supervise HBOT and how facilities should credential providers.
Core UHMS definitional and indication page; explicitly distinguishes true HBOT from 'mild hyperbaric oxygen' use.
The research corpus does not support one universal wellness dose. Murph should log the prescribed pressure units, oxygen fraction, chamber type, session duration, air breaks, planned course, completed sessions, and supervision status.
10 sources · 5 supporting sources · 3 trials · 1 review
Formal boundary statement on what does and does not qualify as HBOT, including the 1.4 ATA and oxygen-concentration distinction. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on DOI 10.22462/07.08.2018.15. Shard claim-use guesses differed.
Most recent synthesis located for acute CO poisoning and useful to map how the trial base has been reinterpreted through 2026.
New registry source for performance and inflammatory-marker claims in healthy adults. Registry record; link to later publications if matched, but do not merge blindly.
Foundational chronic PCS randomized trial frequently cited in later HBOT neurorehabilitation literature.
Large military sham-controlled RCT central to later pooled analyses, safety papers, and policy discussions.
Multi-unit audit gives real-world CNS oxygen toxicity incidence under contemporary practice.
Prospective pulmonary-function dataset complementing older pulmonary-toxicity concerns.
Pilot study with both immediate and longer-term patient-reported outcome follow-up.
Major placebo-controlled phase II long-COVID trial and essential direct evidence for balanced synthesis.
Expands the chronic TBI rehabilitation population to remote childhood injury carried into adulthood.
Selected diabetic-foot-ulcer evidence contains guideline-supported referral lanes and favorable synthesis signals, but sham-controlled, multicenter, and real-world counterevidence prevent a generic “HBOT heals wounds” claim.
10 sources · 4 trials · 3 reviews · 3 guidance sources
Core professional HBOT guideline for diabetic foot ulcer use decisions.
Direct synthesis focused on the ischemic subset most often proposed for HBOT referral.
Open-access meta-analysis that many later overviews cite.
Updated direct meta-analysis extending post-2020 diabetic foot HBOT synthesis.
Current international diabetic-foot guidance update and likely one of the most influential recent protocol-facing sources. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 37232034 / DOI 10.1002/dmrr.3644. Shard directness guesses differed; shard claim-use guesses differed.
Major modern randomized diabetic foot ulcer trial with free full text.
Major modern negative/null randomized trial essential for balanced protocol framing.
Later randomized diabetic foot ulcer trial that extends the controlled trial base past 2016.
Large multicenter randomized trial central to modern interpretation of HBOT for ischemic diabetic wounds.
Useful for showing guideline evolution and preserving earlier skepticism about topical oxygen.
Radiation cystitis is the clearest positive late-radiation lane, lower-bowel injury is mixed, soft-tissue radionecrosis remains lower-certainty, and jaw osteoradionecrosis should not borrow pelvic/bladder evidence.
10 sources · 4 trials · 3 guidance sources · 2 supporting sources
Important multidisciplinary ORN management guideline covering where HBOT fits in jaw radionecrosis care pathways.
Specialty-society guideline for chronic radiation proctitis that anchors how proctitis evidence is interpreted clinically.
Current major oncology guideline for radionecrosis management and the role of HBOT in contemporary practice.
Newest cystitis-specific meta-analysis in the direct pelvic injury literature.
Important randomized jaw radionecrosis trial with negative or mixed implications for HBOT in this tissue phenotype.
Key proctitis randomized controlled trial with long-term follow-up framing direct efficacy questions.
Direct pelvic cohort emphasizing patient-reported recovery rather than only clinician-rated healing.
Flagship direct randomized trial for pelvic radiation cystitis with patient-reported outcomes.
Direct radionecrosis randomized evidence for a head-and-neck radiation tissue phenotype within shard scope.
Frequently cited direct cystitis case-series evidence in later reviews.
Decompression illness, gas embolism, carbon monoxide poisoning, crush injury, and traumatic ischemia belong in hospital/emergency pathways. The carbon-monoxide RCT base is internally conflicting, and traumatic-ischemia evidence is supportive but small and heterogeneous.
11 sources · 6 reviews · 3 guidance sources · 2 trials
Early systematic review that frames heterogeneity and uncertainty across acute CO poisoning trials.
High-priority synthesis of randomized CO poisoning evidence and a standard reference for balanced protocol claims. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 21491385 / DOI 10.1002/14651858.cd002041.pub3. Shard directness guesses differed; shard claim-use guesses differed.
Widely cited expert practice recommendations used to contextualize who is considered for HBOT after acute CO exposure.
Highest-priority evidence synthesis spanning acute traumatic wound indications relevant to traumatic ischemia.
Key consensus document for first-aid, transfer, and early management steps before definitive recompression.
Recent open guideline useful for chamber-indication thresholds, timing, and emergency management context.
Newest trauma-focused systematic review found for severe lower-limb soft tissue injury and HBOT.
Most recent synthesis located for acute CO poisoning and useful to map how the trial base has been reinterpreted through 2026.
Current high-visibility review that covers both major diving-related acute HBOT indications in one source.
Largest modern randomized trauma trial located for acute lower-limb injury and HBOT.
Recent randomized dosing trial that addresses how many HBOT sessions might be needed for acute CO poisoning.
Sudden sensorineural hearing loss is an early adjunctive-care lane, not an open-ended hearing-optimization protocol. Meta-analyses lean positive, but primary studies and salvage comparisons are heterogeneous and otologic safety is central.
9 sources · 5 reviews · 2 guidance sources · 2 supporting sources
Foundational earlier AAO-HNS guideline often cited by later SSNHL reviews and protocols.
Widely cited meta-analysis directly comparing adjunctive HBOT with medical therapy alone.
Core US ENT guideline update that frames when HBOT enters SSNHL management discussions.
Recent steroid-adjunct meta-analysis aligned closely with the protocol’s common real-world use case.
Recent meta-analysis that may capture newer cohorts not included in earlier syntheses.
Most focused recent synthesis for middle-ear and other otologic complications in HBOT.
Targeted otologic review centered on the most common HBOT adverse event category.
Useful mixed/negative comparative source with longer-term salvage follow-up and open full text.
Recent open-access adjunctive-corticosteroid cohort directly aligned with common protocol framing.
Small older-adult HBOT studies and biomarker studies are promising but endpoint-specific. They do not justify broad age-reversal, dementia-prevention, cognition-optimization, or performance-recovery claims; registry-only studies are horizon scanning only.
9 sources · 3 trials · 3 supporting sources · 1 physiology study
Cognition-focused review found heterogeneous HBOT signals rather than a single pooled healthy-aging effect.
Core UHMS definitional and indication page; explicitly distinguishes true HBOT from 'mild hyperbaric oxygen' use.
Direct registry-level source for longevity-marker endpoints beyond telomeres. Registry record; link to later publications if matched, but do not merge blindly.
New registry source for performance and inflammatory-marker claims in healthy adults. Registry record; link to later publications if matched, but do not merge blindly.
Authoritative FDA page on cleared HBOT indications, unproven claims, and consumer cautions about chambers.
Anchor sham-controlled cognition trial in healthy aging adults.
Core human biomarker study for telomere and senescence claims. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 33206062 / DOI 10.18632/aging.202188.
Newest direct sham-controlled older-adult physical-performance trial.
In a high-risk diabetic-MCI cohort, HBOT did not beat sham on primary cognition or imaging outcomes.
Mild/soft chambers, topical oxygen, normobaric oxygen, and exercise-with-oxygen protocols may have their own evidence, but they are separate modalities and should not be treated as clinical systemic HBOT evidence.
10 sources · 6 guidance sources · 4 reviews
Policy signal from organized medicine about safety and supervision concerns around mild-hyperbaric marketing and practice drift.
Cleanly separates topical oxygen from systemic HBOT in Medicare policy history and shows that the modalities are handled differently.
Formal boundary statement on what does and does not qualify as HBOT, including the 1.4 ATA and oxygen-concentration distinction. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on DOI 10.22462/07.08.2018.15. Shard claim-use guesses differed.
Regulatory source that explicitly excludes full-body hyperbaric chambers and helps define the topical-oxygen boundary. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on exact URL. Shard claim-use guesses differed.
Professional society statement directly addressing the common misuse of the term 'topical hyperbaric oxygen'.
European consensus statement against unverified mild-hyperbaric wellness and disease claims.
Important adjacent literature for separating exercise-with-oxygen and rehabilitation oxygen from chamber HBOT.
Useful adjacent-variant review because it frames the low-pressure/mild-hyperbaric literature separately from standard HBOT. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 31062232 / DOI 10.1007/s12576-019-00678-5.
Focused paper on the soft-chamber boundary problem, useful for distinguishing clinical HBOT from low-pressure chamber exposure. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 31084683 / DOI 10.7196/samj.2019.v109i4.13524. Shard claim-use guesses differed.
Useful EWOT-adjacent review because wellness marketing often extrapolates from supplemental-oxygen exercise literature.
Safety is stronger than efficacy for a runnable Murph page: untreated pneumothorax, pulmonary/ENT/seizure/glucose/pregnancy/device/medication risks, barotrauma, vision changes, confinement intolerance, oxygen-toxicity seizure, cardiometabolic changes, and fire/device hazards must remain explicit.
11 sources · 5 reviews · 5 supporting sources · 1 guidance source
Helpful code- and engineering-oriented complement to clinical fire-safety literature.
Concise clinical overview of the common complication spectrum and screening/monitoring concerns.
High-yield clinical overview of absolute vs relative contraindications used in routine HBOT screening.
Broadest recent pooled synthesis of adverse-event frequency and type across clinical HBOT studies. Also surfaced in shard(s): boundary-guidelines, wound-problem-wounds, late-radiation-injury, acute-emergent-indications, healthy-aging-longevity. Canonicalized on PMID 37275378 / DOI 10.3389/fmed.2023.1160774. Shard directness guesses differed.
Modern multicenter adverse-event cohort for current monoplace practice patterns.
Most focused recent synthesis for middle-ear and other otologic complications in HBOT.
Important operational safety paper for diabetic patients and session monitoring protocols.
Very large treatment-volume adverse-event audit with operational relevance for incidence ranking.
Prospective ophthalmic follow-up source for lens and refractive changes during HBOT.
Useful for drug-specific exclusion or caution criteria, especially oncology crossover cases.
Directly informs how often pre-treatment imaging changes pulmonary risk assessment before HBOT.
Key randomized trial frequently cited because it contributes mixed or negative evidence within the CO poisoning literature. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 10092916 / DOI 10.5694/j.1326-5377.1999.tb140318.x. Shard directness guesses differed; shard claim-use guesses differed. Foundational clinical series linking early chamber treatment to outcomes after cerebral air embolism. The Acute And Emergent Indications group currently links 37 appraisal-backed sources with clinical supervised scope and no clear advantage, positive, not efficacy evidence interpretation; use the linked appraisals for source-specific caveats.
37 sources · 15 reviews · 11 supporting sources · 8 trials
Early systematic review that frames heterogeneity and uncertainty across acute CO poisoning trials.
High-priority synthesis of randomized CO poisoning evidence and a standard reference for balanced protocol claims. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 21491385 / DOI 10.1002/14651858.cd002041.pub3. Shard directness guesses differed; shard claim-use guesses differed.
Widely cited expert practice recommendations used to contextualize who is considered for HBOT after acute CO exposure.
Highest-priority evidence synthesis spanning acute traumatic wound indications relevant to traumatic ischemia.
Key consensus document for first-aid, transfer, and early management steps before definitive recompression.
Systematic synthesis of case-level evidence in a condition where randomized trials are scarce.
Recent open guideline useful for chamber-indication thresholds, timing, and emergency management context.
Best recent synthesis located for iatrogenic cerebral arterial gas embolism and especially relevant to timing.
Newest trauma-focused systematic review found for severe lower-limb soft tissue injury and HBOT.
Most recent synthesis located for acute CO poisoning and useful to map how the trial base has been reinterpreted through 2026.
Key randomized trial frequently cited because it contributes mixed or negative evidence within the CO poisoning literature. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 10092916 / DOI 10.5694/j.1326-5377.1999.tb140318.x. Shard directness guesses differed; shard claim-use guesses differed.
Foundational clinical series linking early chamber treatment to outcomes after cerebral air embolism.
Most-cited modern RCT in acute CO poisoning and a central source for protocol-level evidence review.
Orthopedic review that helps map how trauma surgeons frame HBOT in severe extremity injury.
Direct, indication-specific review focused exactly on the traumatic ischemia boundary of this shard.
Direct HBOT-treated cohort useful for describing prognostic features among acute CO poisoning referrals.
Later randomized evidence directly relevant to unresolved treatment questions in acute CO poisoning.
High-impact review spanning decompression sickness and arterial gas embolism, useful for protocol framing and references.
Focused review on crush injury and compartment syndrome mechanisms and clinical rationale for acute HBOT use.
Large observational cohort providing long-term outcome context around acute CO poisoning populations considered for HBOT.
Foundational randomized comparison in acute CO poisoning and part of the core trial set behind HBOT practice debates.
Trial protocol that clarifies design, endpoints, and target population for the later HOLLT study.
Modern hyperbaric-unit cohort on iatrogenic cerebral gas embolism, useful for case mix and referral patterns.
Large comparative cohort directly relevant to mortality outcomes in acute CO poisoning.
Frequently cited U.S. observational study on acute CO poisoning outcomes and mortality with HBOT exposure.
Direct recommendation-style review for one of the main acute emergent HBOT indications.
Directly relevant timing study for emergency HBOT initiation after acute CO poisoning.
Prospective multicenter observational evidence focused on delayed neurologic outcomes after acute CO poisoning.
Current high-visibility review that covers both major diving-related acute HBOT indications in one source.
Largest modern randomized trauma trial located for acute lower-limb injury and HBOT.
Recent randomized dosing trial that addresses how many HBOT sessions might be needed for acute CO poisoning.
Newest recommendation-style review located for gas embolism, useful for current standard-of-care framing.
Newest recommendation-style review located for decompression sickness, useful for current practice framing.
Foundational delayed-treatment series directly relevant to one of the shard’s key endpoint families.
Influential randomized trial focused on delayed neuropsychological outcomes after acute CO poisoning.
Classic retrospective spinal-cord DCS series directly tied to severity and timing questions.
Seminal randomized trial for acute traumatic ischemia and crush injury, one of the few controlled studies in this subfield.
Representative clinic marketing page tying direct HBOT aging studies to premium anti-aging claims. Excluded from extraction; keep only for audit or why-excluded context. Professional society statement directly addressing the common misuse of the term 'topical hyperbaric oxygen'. The Adjacent Modalities And External Claims group currently links 20 appraisal-backed sources with direct protocol, adjacent variant, general guideline scope and not efficacy evidence interpretation; use the linked appraisals for source-specific caveats.
20 sources · 8 supporting sources · 5 reviews · 4 trials
Representative clinic marketing page tying direct HBOT aging studies to premium anti-aging claims. Excluded from extraction; keep only for audit or why-excluded context.
Professional society statement directly addressing the common misuse of the term 'topical hyperbaric oxygen'.
European consensus statement against unverified mild-hyperbaric wellness and disease claims.
Representative commercial EWOT claims page for auditing non-chamber oxygen wellness marketing. Excluded from extraction; keep only for audit or why-excluded context.
Authoritative FDA page on cleared HBOT indications, unproven claims, and consumer cautions about chambers.
Manufacturer/distributor page showing how mild-chamber wellness claims are framed for consumers. Excluded from extraction; keep only for audit or why-excluded context.
Important adjacent literature for separating exercise-with-oxygen and rehabilitation oxygen from chamber HBOT.
Frequently cited in mild-chamber/autism marketing; important boundary case because exposure does not match standard systemic HBOT definitions. Excluded from extraction; keep only for audit or why-excluded context.
Useful review for separating stroke-related normobaric hyperoxia literature from HBOT claims.
Clear example of a review that directly compares normobaric and hyperbaric oxygen rather than treating them as interchangeable.
Broad oxygen-therapy meta-analysis that may pool modalities and therefore matters for variant separation.
Modern pivotal RCT for topical wound oxygen; crucial for distinguishing topical-ulcer evidence from systemic HBOT evidence.
Useful for showing guideline evolution and preserving earlier skepticism about topical oxygen.
Older randomized topical-oxygen trial often cited in boundary debates and important for negative/mixed evidence retention.
Useful EWOT-adjacent review because wellness marketing often extrapolates from supplemental-oxygen exercise literature.
Another contemporary topical-oxygen RCT useful for boundary-setting against systemic HBOT claims.
Broad scoping review that helps map topical oxygen subtypes and terminology drift.
Recent broad review for mapping the wound-healing oxygen landscape around HBOT.
Representative large-chain mHbOT marketing page making broad wellness and recovery claims that need audit. Excluded from extraction; keep only for audit or why-excluded context.
Strong example of EWOT marketing that makes disease-prevention, cancer, and anti-aging claims outside HBOT evidence boundaries. Excluded from extraction; keep only for audit or why-excluded context.
Direct randomized multicentre registry entry that may become a pivotal future source once results post. Registry record; link to later publications if matched, but do not merge blindly. Early direct clinical HBOT study frequently cited in later evidence syntheses. The ENT And Sudden Sensorineural Hearing Loss group currently links 38 appraisal-backed sources with clinical supervised, adjacent variant, general guideline scope and not efficacy evidence, positive, mixed interpretation; use the linked appraisals for source-specific caveats.
38 sources · 21 supporting sources · 11 reviews · 4 trials
Early Cochrane review anchoring the evidence base for HBOT in SSHL/tinnitus discussions.
Foundational evidence synthesis focused on randomized HBOT evidence for SSHL/tinnitus-era literature.
Foundational earlier AAO-HNS guideline often cited by later SSNHL reviews and protocols.
Updated Cochrane synthesis that remains a major reference point for older HBOT hearing-loss trials.
Widely cited meta-analysis directly comparing adjunctive HBOT with medical therapy alone.
Focused ENT systematic review that helps bridge older trials to more recent comparative studies.
Core US ENT guideline update that frames when HBOT enters SSNHL management discussions.
Key salvage-focused synthesis for a common clinical decision boundary: HBOT versus intratympanic steroid rescue.
High-visibility modern meta-analysis that re-aggregates direct clinical HBOT evidence for SSNHL.
Recent steroid-adjunct meta-analysis aligned closely with the protocol’s common real-world use case.
Recent meta-analysis that may capture newer cohorts not included in earlier syntheses.
Recent hyperbaric-journal systematic review/meta-analysis focused tightly on acute idiopathic SSNHL.
Direct randomized multicentre registry entry that may become a pivotal future source once results post. Registry record; link to later publications if matched, but do not merge blindly.
Early direct clinical HBOT study frequently cited in later evidence syntheses.
Foundational comparative HBOT study repeatedly included in later reviews and meta-analyses.
Older direct study central to historical comparisons of HBOT plus standard care versus standard care alone.
Important early combination-therapy study tying HBOT to steroid-based management of SSNHL.
Prospective salvage-era study relevant to delayed or refractory HBOT use.
Boundary source for chronic tinnitus discussions that should stay separate from SSNHL-aligned protocol claims.
Large retrospective comparison with audiologically controlled follow-up, useful for real-world context.
Key randomized prospective salvage comparison directly relevant to post-steroid decision making.
Prospective salvage study adding controlled comparative evidence after initial-treatment failure.
Direct comparative study often cited in later meta-analyses and editorial debate.
Direct salvage paper from ENT literature relevant to delayed HBOT use scenarios.
Modern randomized direct-comparison trial in a severe/profound SSNHL subgroup.
Adds direct cohort evidence and subgroup/prognostic context for combined HBOT treatment.
Useful mixed/negative comparative source with longer-term salvage follow-up and open full text.
Large retrospective barotrauma source directly relevant to ENT-facing HBOT safety counseling.
Recent open-access comparative study focusing on severe/profound SSNHL subgroups.
Open-access cohort useful for effect-modifier and prognostic context within HBOT-treated populations.
Protocol-optimization study useful for dose/timing regimen details rather than simple efficacy framing.
Recent direct ENT cohort centered on final audiometric outcomes after HBOT exposure.
Recent salvage-comparison study in a high-impact audiology journal.
Recent open-access adjunctive-corticosteroid cohort directly aligned with common protocol framing.
Direct salvage-comparison study in a contemporary steroid background regimen.
Direct refractory-salvage study closely aligned to current escalation pathways.
Recent open-access case-control study adding contemporary direct evidence for combined HBOT plus steroids.
Older randomized comparative study that helps map the earliest clinical HBOT hearing-loss literature.
Older registry-only MCI study that may explain gaps between published and unpublished evidence. Registry record; link to later publications if matched, but do not merge blindly. Registry counterpart for the major diabetic-MCI cognition program, useful for design and completion tracking. Registry record; link to later publications if matched, but do not merge blindly. The Healthy Aging Longevity And Off Label Wellness group currently links 33 appraisal-backed sources with clinical supervised, adjacent variant, same mechanism scope and not efficacy evidence, positive, no clear advantage interpretation; use the linked appraisals for source-specific caveats.
33 sources · 13 reviews · 8 trials · 6 supporting sources
Cognition-focused review found heterogeneous HBOT signals rather than a single pooled healthy-aging effect.
Older registry-only MCI study that may explain gaps between published and unpublished evidence. Registry record; link to later publications if matched, but do not merge blindly.
Registry counterpart for the major diabetic-MCI cognition program, useful for design and completion tracking. Registry record; link to later publications if matched, but do not merge blindly.
Direct registry-level source for longevity-marker endpoints beyond telomeres. Registry record; link to later publications if matched, but do not merge blindly.
Ongoing registry signal for a directly relevant prodromal-AD aging population. Registry record; link to later publications if matched, but do not merge blindly.
New registry source for performance and inflammatory-marker claims in healthy adults. Registry record; link to later publications if matched, but do not merge blindly.
Older formal evidence synthesis that should not be skipped when older dementia evidence is cited.
Later meta-analytic update on dementia-adjacent efficacy and safety.
Human dementia-adjacent efficacy source relevant to cognitive claims but outside healthy aging populations.
Design paper for a major sham-controlled mild-impairment trial in a high-risk older cohort.
Direct mild-impairment/dementia-adjacent human outcome study frequently cited in the aging literature.
Anchor sham-controlled cognition trial in healthy aging adults.
Core human biomarker study for telomere and senescence claims. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 33206062 / DOI 10.18632/aging.202188.
Disease-specific review covering dementia-adjacent evidence and mechanisms.
Mixed preclinical/human mechanistic paper linking HBOT to vascular and amyloid-related aging pathways.
Mechanistic review frequently cited for cognition-related HBOT rationale.
Useful boundary evidence for anti-aging/skin-rejuvenation claims in healthy aging populations.
Human mechanistic study relevant to aging-pathway claims.
Important mixed/negative synthesis for performance and recovery claims.
Best sham-controlled physical-performance trial outside older-adult populations.
Most on-point healthy-aging review and a strong map of the field. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 35649312 / DOI 10.1016/j.redox.2022.102352. Shard directness guesses differed.
Useful review for vascular-aging framing and mechanistic rationale.
Mechanistic background review for hyperoxia-related aging biomarker claims beyond HBOT-specific trials.
Direct but very low-N human report linking HBOT with cognition, performance, and telomere outcomes; useful as a boundary source, not as confirmatory efficacy evidence.
Important for interpreting HBOT trial controls and mechanism claims because hyperbaric air itself may have biologic effects; boundary evidence for aging/longevity mechanisms rather than direct efficacy.
Boundary review on aesthetic/anti-aging uses and associated safety framing. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 38356446 / DOI 10.1111/jocd.16228. Shard directness guesses differed.
Most recent formal AD meta-analysis and a good cross-check against primary sources.
Newest direct sham-controlled older-adult physical-performance trial.
Useful boundary synthesis where wellness-marketing claims often originate. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 39733047 / DOI 10.1007/s00266-024-04553-6. Shard directness guesses differed.
Newest sports-recovery meta-analysis and a check against more promotional performance claims.
In a high-risk diabetic-MCI cohort, HBOT did not beat sham on primary cognition or imaging outcomes.
Very early oxygen/cognition source that helps bracket historical claims.
Foundational older clinical trial that predates current HBOT aging claims.
Mechanistic wound-oxygen review that helps separate oxygen-biology context from direct HBOT protocol evidence. Foundational review on ICU-relevant HBOT use that can support context around higher-acuity program requirements. The Identity Boundary Supervision And Variant Separation group currently links 36 appraisal-backed sources with same mechanism, general guideline, direct protocol scope and not efficacy evidence, positive interpretation; use the linked appraisals for source-specific caveats.
36 sources · 18 guidance sources · 17 reviews · 1 physiology study
Policy signal from organized medicine about safety and supervision concerns around mild-hyperbaric marketing and practice drift.
Foundational CMS wound-indication memo that also discusses physician supervision and credentialing issues around HBOT delivery.
U.S. coverage anchor defining HBOT as whole-body exposure and listing covered vs non-covered indication classes.
Cleanly separates topical oxygen from systemic HBOT in Medicare policy history and shows that the modalities are handled differently.
Formal boundary statement on what does and does not qualify as HBOT, including the 1.4 ATA and oxygen-concentration distinction. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on DOI 10.22462/07.08.2018.15. Shard claim-use guesses differed.
Regulatory source that explicitly excludes full-body hyperbaric chambers and helps define the topical-oxygen boundary. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on exact URL. Shard claim-use guesses differed.
Operational supervision statement that specifies direct supervision expectations and immediate physician availability.
Foundational older European practice code that remains useful for historical boundary-setting and practice evolution.
Consensus statement directly addressing physician qualification and supervision requirements for HBOT delivery.
Boundary review that is explicitly focused on unestablished indications and helps preserve negative or unsupported use-cases. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 25596836. Shard directness guesses differed.
Specialty-specific supervision guidance relevant to wound-focused HBOT practice environments.
ECHM position statement that adds detail on practice requirements when HBOT is used in ICU-level contexts.
Major European consensus document mapping accepted versus non-accepted HBOT indications and practice boundaries. Also surfaced in shard(s): late-radiation-injury, ent-hearing, healthy-aging-longevity. Canonicalized on PMID 28357821 / DOI 10.28920/dhm47.1.24-32. Shard directness guesses differed; shard claim-use guesses differed.
Comprehensive practice code covering operational, supervision, and treatment-process boundaries for HBOT.
Peer-reviewed UHMS position statement detailing physician responsibilities for HBOT prescription, monitoring, and proximity.
Direct U.S. practice-standard document on who may supervise HBOT and how facilities should credential providers.
Core UHMS definitional and indication page; explicitly distinguishes true HBOT from 'mild hyperbaric oxygen' use.
Core professional reference for what counts as clinical HBOT and which indications the field recognizes. Discovered in shard(s): adjacent-modalities-and-external-claims; rebucketed to boundary-guidelines for extraction.
Sets expectations that office-based HBOT should meet the same standards and accreditation logic as hospital-based HBOT.
Mechanistic wound-oxygen review that helps separate oxygen-biology context from direct HBOT protocol evidence.
Foundational review on ICU-relevant HBOT use that can support context around higher-acuity program requirements.
Helpful cross-modality review for distinguishing HBOT from topical and other oxygen-based wound treatments.
Method paper that helps separate strong from weak indication claims and prevents overstatement in protocol synthesis.
Boundary review for topical oxygen therapies, useful to prevent conflating topical wound oxygen with HBOT evidence. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 25647433 / DOI 10.12968/jowc.2015.24.2.53.
Useful staffing-focused review to supplement formal position statements on supervision and training boundaries.
Broad clinical overview review that is useful for mapping how mainstream literature describes HBOT use and evidence boundaries.
Useful adjacent-variant review because it frames the low-pressure/mild-hyperbaric literature separately from standard HBOT. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 31062232 / DOI 10.1007/s12576-019-00678-5.
Focused paper on the soft-chamber boundary problem, useful for distinguishing clinical HBOT from low-pressure chamber exposure. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 31084683 / DOI 10.7196/samj.2019.v109i4.13524. Shard claim-use guesses differed.
Systematic review of a common adjacent modality that should not be merged into systemic HBOT evidence without clear separation. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 33871095 / DOI 10.1111/dme.14585.
High-level overview review helpful for orientation and terminology, though not a boundary-setting source by itself.
Useful adjacent-modality overview for diabetic foot ulcer wound oxygen literature that should remain distinct from systemic HBOT evidence. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 34577840 / DOI 10.3390/medicina57090917.
Recent synthesis of topical wound oxygen evidence that can otherwise be mistakenly imported into HBOT efficacy discussions. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 35593010 / DOI 10.1089/wound.2022.0041.
Recent safety-focused review that may help triangulate contemporary adverse-event framing and mitigation.
Directly relevant dose-boundary paper comparing low-pressure exposure with standard HBOT-range exposure.
Cross-modality oxygen-therapy review that may be useful for identifying where evidence streams are blended and need separation. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 38648247 / DOI 10.1097/asw.0000000000000131. Shard directness guesses differed.
Newest broad review of topical oxygen therapy, useful for keeping adjacent wound-oxygen evidence separate from systemic HBOT.
Direct cystitis cohort often used to contextualize later trial and review literature. Foundational pelvic late-radiation injury series often cited in later HBOT reviews and guidelines. The Late Radiation Tissue Injury group currently links 38 appraisal-backed sources with clinical supervised, same mechanism, adjacent variant scope and positive, not efficacy evidence, no clear advantage interpretation; use the linked appraisals for source-specific caveats.
38 sources · 20 supporting sources · 8 reviews · 7 trials
Foundational systematic review for the field; useful to preserve older synthesis and trial context.
Important multidisciplinary ORN management guideline covering where HBOT fits in jaw radionecrosis care pathways.
Cystitis-focused synthesis that aggregates earlier heterogeneous direct studies before newer registry and RCT follow-up data.
Specialty-society guideline for chronic radiation proctitis that anchors how proctitis evidence is interpreted clinically.
Population-focused systematic review on pelvic and gynecologic late-radiation injury outcomes.
Most important cross-indication evidence synthesis for this shard and its subphenotypes.
Current major oncology guideline for radionecrosis management and the role of HBOT in contemporary practice.
Newest cystitis-specific meta-analysis in the direct pelvic injury literature.
Newest shard-focused review centering bowel and bladder late-radiation injury phenotypes.
Direct cystitis cohort often used to contextualize later trial and review literature.
Foundational pelvic late-radiation injury series often cited in later HBOT reviews and guidelines.
Important randomized jaw radionecrosis trial with negative or mixed implications for HBOT in this tissue phenotype.
Cystitis cohort focused on timing of HBOT and clinical response.
Gynecologic-oncology late-radiation injury series relevant to pelvic soft tissue endpoints.
GI-focused direct series relevant to bowel bleeding, urgency, and healing outcomes.
Key proctitis randomized controlled trial with long-term follow-up framing direct efficacy questions.
Gynecologic oncology review and practice-guidance style paper squarely focused on pelvic late-radiation injury.
Large prospective observational series spanning several late-radiation injury phenotypes.
Direct pelvic cohort emphasizing patient-reported recovery rather than only clinician-rated healing.
Large regional cohort that broadens direct late-radiation injury evidence beyond pelvic-only series.
Major negative or mixed sham-controlled pelvic bowel trial that prevents survivorship literature from appearing one-sided.
Adjacent soft-tissue radionecrosis review relevant to broader LRTI healing mechanisms and tissue endpoints.
Boundary prevention RCT relevant to prophylactic peri-radiation and post-radiation surgical settings rather than established late tissue injury treatment.
Flagship direct randomized trial for pelvic radiation cystitis with patient-reported outcomes.
Shows direct late-radiation injury experience outside pelvic oncology and broadens tissue-injury context.
Long-term cystitis follow-up addresses durability questions not captured by acute response papers alone.
Direct pelvic LRTI observational study aligned closely with this shard's symptom and QoL endpoints.
Useful for implementation and regimen-comparison questions inside the direct cystitis literature.
Direct radionecrosis randomized evidence for a head-and-neck radiation tissue phenotype within shard scope.
Recent pelvic survivorship study centered on symptom burden and health-related quality of life.
Recent proctitis-specific cohort that can be compared against earlier randomized and observational bowel evidence.
Classic preventive ORN randomized study; relevant as an adjacent peri-radiation protocol rather than established LRTI treatment.
Recent administrative-data study with potential signal on real-world cystitis outcomes and utilization.
Direct long-term follow-up of the leading cystitis randomized trial, essential for durability questions.
Early cystitis-specific clinical series that anchors the historical direct evidence base.
Broad abdomen/pelvis delayed-radiation injury cohort covering multiple target tissues in this shard.
Older proctitis-specific direct evidence preceding later randomized work.
Frequently cited direct cystitis case-series evidence in later reviews.
Foundational older systematic review that captures the pre-chronic-PCS HBOT evidence base. Foundational early phase I chronic blast-related PCS/PTSD HBOT study that shaped later low-pressure trial programs. The Neurocognitive And Restorative Clinical HBOT group currently links 40 appraisal-backed sources with adjacent variant, clinical supervised, general guideline scope and not efficacy evidence, positive, mixed interpretation; use the linked appraisals for source-specific caveats.
40 sources · 15 trials · 12 supporting sources · 10 reviews
Direct practice-guideline source that explicitly addresses HBOT in post-acute mTBI management.
Focused systematic review for the shard’s main cognitive outcome family.
Recent direct-review source focused specifically on persistent PCS rather than acute TBI. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 35370898 / DOI 10.3389/fneur.2022.815056. Shard directness guesses differed; shard claim-use guesses differed.
Broad early systematic review for the long-COVID HBOT evidence base.
Newest TBI neurocognition-focused quantitative synthesis identified in this shard.
Newest long-COVID cognition-focused review identified in this shard.
Foundational older systematic review that captures the pre-chronic-PCS HBOT evidence base.
Foundational early phase I chronic blast-related PCS/PTSD HBOT study that shaped later low-pressure trial programs.
Key sham-controlled military mTBI trial and important null or mixed-evidence anchor for the field.
High-quality acute/mixed-TBI review that helps separate chronic restorative claims from ICU neuroprotection evidence.
Widely cited sham-controlled military PCS outcomes paper with medium-term follow-up.
Foundational chronic PCS randomized trial frequently cited in later HBOT neurorehabilitation literature.
Direct sham-controlled PCS trial with explicit cognitive and psychomotor endpoints.
Major randomized clinical trial in military PCS often used in evidence reviews and guideline discussions.
Adds direct neurocognitive endpoint detail beyond global symptom outcomes in the military trial program.
Direct PCS-focused review that provides field context, mechanisms, and research framing around HBOT.
Influential structured review used in later discussions of trial design, sham issues, and evidence interpretation.
Mechanistic TBI paper aligned with the shard’s neuroplasticity and imaging endpoint family.
Direct chronic PCS cohort with PTSD overlap and pragmatic case-control design.
Large military sham-controlled RCT central to later pooled analyses, safety papers, and policy discussions.
Direct sleep-endpoint paper from the military randomized HBOT program.
Large chronic post-TBI retrospective series focused on neurocognitive recovery rather than acute neuroprotection.
Large real-world multicenter cohort that broadens the evidence base beyond military and single-center trials.
Direct safety and sham-integrity source for the mTBI/post-concussion randomized trial program.
Later randomized chronic PCS study from a different research group and dosing approach than the military program.
One of the earliest long-COVID HBOT clinical reports and useful for chronology of the field.
Foundational sham-controlled long-COVID RCT directly aligned with the shard’s neurocognitive restorative focus.
Important pediatric randomized PCS source and population-expansion paper.
Direct mechanistic imaging companion to the post-COVID sham-controlled RCT program.
Key protocol paper for the HOT-LoCO long-COVID randomized trial and useful for pre-specified outcomes and methods.
Early post-COVID clinical cohort that adds non-Israeli and non-HOT-LoCO experience.
Direct safety source for the long-COVID placebo-controlled HBOT trial platform.
Pilot study with both immediate and longer-term patient-reported outcome follow-up.
Adds durability and follow-up information to the post-COVID sham-controlled RCT evidence.
Useful counterweight and critical appraisal source rather than a purely promotional review.
Recent double-blind randomized non-stroke brain injury trial extending the PCS evidence base beyond older military cohorts.
Major placebo-controlled phase II long-COVID trial and essential direct evidence for balanced synthesis.
Boundary evidence because it mixes normobaric and hyperbaric hyperoxia rather than isolating standard HBOT alone.
Prospective registry extends the evidence base beyond single RCT platforms and helps with real-world generalizability.
Expands the chronic TBI rehabilitation population to remote childhood injury carried into adulthood.
Blinded randomized evidence directly relevant to ischemic diabetic foot ulcers. Randomized nonischemic diabetic foot ulcer trial focused on healing rate and wound evolution. The Problem Wounds And Diabetic Foot Ulcers group currently links 39 appraisal-backed sources with clinical supervised, same mechanism, adjacent variant scope and positive, not efficacy evidence, no clear advantage interpretation; use the linked appraisals for source-specific caveats.
39 sources · 18 reviews · 9 trials · 6 guidance sources
Direct diabetic foot ulcer review from a major clinical review venue.
Formal technology-assessment meta-analysis directly focused on diabetic ulcers.
Frequently cited direct review used by subsequent guidelines and evidence summaries.
Core professional HBOT guideline for diabetic foot ulcer use decisions.
Widely used international diabetic-foot guidance covering HBOT among healing adjuncts.
Major wound-care society guideline relevant to protocol positioning in standard DFU care.
Focused meta-analysis of clinical trials in diabetes-related lower-limb ulcer populations.
Useful review separating nonischemic diabetic ulcers from the ischemic subgroup.
Direct synthesis focused on the ischemic subset most often proposed for HBOT referral.
Open-access meta-analysis that many later overviews cite.
Updated direct meta-analysis extending post-2020 diabetic foot HBOT synthesis.
Current international diabetic-foot guidance update and likely one of the most influential recent protocol-facing sources. Also surfaced in shard(s): adjacent-modalities-and-external-claims. Canonicalized on PMID 37232034 / DOI 10.1002/dmrr.3644. Shard directness guesses differed; shard claim-use guesses differed.
Current major wound-care society guideline update relevant to HBOT placement in DFU care.
Newest direct DFU meta-analysis with a grading-based lens that may matter for protocol scoping.
Newest systematic review on a modern compromised-flap reconstructive application.
Blinded randomized evidence directly relevant to ischemic diabetic foot ulcers.
Randomized nonischemic diabetic foot ulcer trial focused on healing rate and wound evolution.
Foundational early controlled trial directly testing adjunctive HBOT in diabetic foot disease.
Early Cochrane review that anchors the historical evidence base for chronic wounds and DFU.
Key evidence appraisal for the graft/flap salvage branch of the shard.
Direct diabetic foot ulcer trial that is regularly pooled in later meta-analyses.
Major modern randomized diabetic foot ulcer trial with free full text.
Useful for patient-selection and response-stratification context within direct DFU HBOT use.
Important negative observational study that must remain visible alongside positive trials.
Direct clinical flap-salvage series from an HBOT specialty journal.
Major modern negative/null randomized trial essential for balanced protocol framing.
Useful context source because HBOT is assessed inside a broader adjunctive-therapy evidence map.
Accessible graft/flap salvage review in a wound-care journal with free full text.
Later randomized diabetic foot ulcer trial that extends the controlled trial base past 2016.
Large multicenter randomized trial central to modern interpretation of HBOT for ischemic diabetic wounds.
Comparative nonrandomized diabetic foot ulcer study focused on nonischemic wounds.
Direct reconstructive-salvage cohort relevant to the graft/flap salvage branch.
Directly addresses the “selected problem wounds” boundary of the shard.
Recent graft/flap-focused review building on earlier appraisal literature.
Modern flap-salvage cohort in a clearly defined reconstructive population.
Boundary source to keep local/topical oxygen distinct from systemic HBOT in this shard.
Keep for literature-QC tracking because the publisher page flags this 2024 meta-analysis as retracted. Excluded from extraction; keep only for audit or why-excluded context.
Keep for literature-QC tracking because this 2024 meta-analysis is also marked retracted and should not drive protocol claims. Excluded from extraction; keep only for audit or why-excluded context.
Landmark randomized diabetic foot ulcer trial frequently cited in later reviews and guidelines.
Recent review that updates the chamber-fire literature and hazard framing. Early prevention study frequently cited in later otologic management discussions. The Safety Contraindications Adverse Events And Facility Hazards group currently links 40 appraisal-backed sources with general guideline scope and not efficacy evidence interpretation; use the linked appraisals for source-specific caveats.
40 sources · 22 supporting sources · 11 reviews · 5 guidance sources
Authoritative regulator communication on recent serious injuries and deaths plus preventive actions. Also surfaced in shard(s): boundary-guidelines, adjacent-modalities-and-external-claims. Canonicalized on exact URL.
Helpful code- and engineering-oriented complement to clinical fire-safety literature.
Foundational review repeatedly cited in later HBOT safety literature. Also surfaced in shard(s): boundary-guidelines, acute-emergent-indications, ent-hearing. Canonicalized on PMID 10685584. Shard directness guesses differed.
Widely cited review that operationalizes common HBOT side effects for clinical practice. Also surfaced in shard(s): acute-emergent-indications, healthy-aging-longevity. Canonicalized on PMID 28616361 / DOI 10.1089/wound.2016.0718. Shard directness guesses differed.
Concise clinical overview of the common complication spectrum and screening/monitoring concerns.
High-yield clinical overview of absolute vs relative contraindications used in routine HBOT screening.
Broadest recent pooled synthesis of adverse-event frequency and type across clinical HBOT studies. Also surfaced in shard(s): boundary-guidelines, wound-problem-wounds, late-radiation-injury, acute-emergent-indications, healthy-aging-longevity. Canonicalized on PMID 37275378 / DOI 10.3389/fmed.2023.1160774. Shard directness guesses differed.
Modern multicenter adverse-event cohort for current monoplace practice patterns.
Most focused recent synthesis for middle-ear and other otologic complications in HBOT.
Narrow but directly relevant study on airway status as a modifier of ear-complication risk.
Important when considering prophylactic tube placement to avoid or manage HBOT intolerance.
Major facility operations reference used by accredited HBOT programs and cited in UHMS safety materials.
Older foundational multiplace operations document still useful for historical safety norms and hazards.
Recent post-incident patient-facing safety statement from the major professional society.
Recent review that updates the chamber-fire literature and hazard framing.
Early prevention study frequently cited in later otologic management discussions.
Foundational seizure-incidence series used as a benchmark in later safety reviews.
Adds direct case-level evidence that cataract formation can occur after clinical HBOT exposure.
Useful for seizure-threshold modifiers and case-level risk enrichment factors.
Key review of device compatibility and procedure controversies inside the chamber. Also surfaced in shard(s): boundary-guidelines. Canonicalized on PMID 25596835. Shard directness guesses differed.
Important operational safety paper for diabetic patients and session monitoring protocols.
Large direct seizure-incidence dataset for one of the most feared HBOT complications.
Large single-program safety cohort that helps size the adverse-event burden in routine HBOT practice.
Direct clinical cohort for dose-related visual acuity change during standard HBOT courses.
Very large treatment-volume adverse-event audit with operational relevance for incidence ranking.
Convenient overview linking repeated oxygen exposure to lens-related adverse effects.
Useful for pre-treatment screening of patients most likely to fail pressure equalization.
Multi-unit audit gives real-world CNS oxygen toxicity incidence under contemporary practice.
Prospective ophthalmic follow-up source for lens and refractive changes during HBOT.
Targeted otologic review centered on the most common HBOT adverse event category.
Prospective pulmonary-function dataset complementing older pulmonary-toxicity concerns.
Useful for drug-specific exclusion or caution criteria, especially oncology crossover cases.
Useful for cardiovascular screening and monitoring thresholds during treatment courses.
Directly informs how often pre-treatment imaging changes pulmonary risk assessment before HBOT.
Modern longitudinal pulmonary-safety study relevant to COPD/asthma and repeated-course concerns.
Direct subgroup evidence for a commonly discussed relative contraindication.
Direct patient data for implantable-device compatibility questions that often arise during screening.
Current focused review on one of the highest-stakes in-chamber emergency/device hazards.
Older foundational ophthalmic paper frequently cited in HBOT ocular-risk discussions.
Foundational fire-hazard epidemiology source for chamber ignition and fatality patterns. Also surfaced in shard(s): boundary-guidelines. Canonicalized on PMID 9308138.